Can I stay on 2.5 mg of Zepbound if it’s working?
Not according to the US label. Zepbound (tirzepatide) starts at 2.5 mg once a week for 4 weeks, then goes up to 5 mg. The label’s long-term (maintenance) doses for weight are 5 mg, 10 mg or 15 mg a week, and it says 2.5 mg “is not approved as a maintenance dosage.”
- GLP‑1 medicines are prescription-only in the US. Your prescriber decides your dose.
- Dose facts here come from the US prescribing information for Zepbound. Prices are Eli Lilly’s own self-pay prices, with the date we checked them.
- Nothing here promises any result, and nothing here is for sale.
What does the Zepbound label say about the 2.5 mg dose?
The US label calls 2.5 mg the starting dose: one injection a week for 4 weeks, then up to 5 mg.1
The label’s words: “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”1 The slow start is there “to reduce the risk of gastrointestinal adverse reactions” such as nausea.1 Lilly’s own savings page says it too: “Zepbound 2.5 mg is for initiation only.”4
After 5 mg, each further 2.5 mg step comes “after at least 4 weeks on the current dose.” The maintenance dose for weight is 5, 10 or 15 mg, chosen on “treatment response and tolerability.” If one isn’t tolerated, the label says to “consider a lower maintenance dosage,” and the lowest is 5 mg.1 The FDA says prescribers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.”8
How much weight did people lose on each dose in the trial?
In Zepbound’s main 72-week trial, average weight loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg.2
People on a placebo (dummy injection) lost 3.1%. These are averages: some people lost more, some less. 85 in 100 people on 5 mg lost at least 5% of their weight, against 35 in 100 on placebo.2 Every group started on 2.5 mg and went up by 2.5 mg every 4 weeks to its assigned dose. No group stayed on 2.5 mg,3 so we found no trial result for 2.5 mg as a long-term dose.
Stomach effects came with every dose. In the weight trials in the US label, nausea hit 25 in 100 people on 5 mg and 28 in 100 on 15 mg. On placebo it was 8 in 100. Most nausea, vomiting and diarrhea happened “during dose escalation and decreased over time.”1
Zepbound’s schedule from your first dose, with each label section cited.
Will insurance keep paying for 2.5 mg?
Some plans approve only 5, 10 or 15 mg once the starting weeks are over, and others still pay for 2.5 mg every month.5,6
One Rhode Island plan’s 2026 policy approves continued treatment, after 20 weeks, only at “5, 10, or 15 mg.”5 Cigna’s national formulary dropped its once-a-year limit on 2.5 mg in January 2025. It now allows 4 pens or vials every 28 days.6 Your own plan’s policy is the one that counts. Coverage routes are in Guide 6.
Without insurance, Lilly charges $299 a month for 2.5 mg vials or KwikPens and $399 for 5 mg. We checked on October 19, 2026.4 Every dose is in How much is Zepbound without insurance?
What do people on Zepbound report about staying on 2.5 mg?
From public patient forums: 8 Reddit threads in r/Zepbound and r/WegovyWeightLoss (2 of them about Wegovy’s starting dose), read in October 2026. Personal reports, not medical evidence.
What people describe
- Label says otherwise Many say they stayed on 2.5 mg for months and kept losing weight, often to save money. The US label says 2.5 mg “is not approved as a maintenance dosage.”1
- Matches the label Several say stomach side effects got much worse at 5 mg. In the weight trials in the US label, 25 in 100 people on 5 mg had nausea, against 8 in 100 on placebo.1
- Label says otherwise A few say they went back to 2.5 mg when 5 mg made them ill. The label’s answer is a lower maintenance dose, and its lowest is 5 mg.1
- Matches the trial Several say they saw little change below 5 mg. In the main trial, average loss rose with dose, from 15.0% on 5 mg to 20.9% on 15 mg.2 The trial had no long-term 2.5 mg group.3
- Matches the label Several say insurance paid for only one or a few months of 2.5 mg. One plan we read approves continued treatment, after 20 weeks, only at the label’s maintenance doses: “5, 10, or 15 mg.”1,5
Advice people share
- Matches the label Most replies say to move up only when appetite control fades or weight stalls. From 5 mg up, that fits the label, which picks the maintenance dose on response and tolerability.1
- Label says otherwise Several describe spacing 2.5 mg shots more than a week apart. The label says to use Zepbound “1 time each week.”1 We found no study of spacing out doses.
- Label says otherwise Several describe splitting pens or vials to make doses the label doesn’t list. The label says the KwikPen holds “4 fixed doses” and opened single-dose vials are thrown away “even if there is medicine left.”1
- Label says otherwise Several suggest compounded tirzepatide for smaller dose steps. The FDA says “compounded drugs are not FDA approved.”7
- Stomach effects are common. In the weight trials in the US label, 25 to 29 in 100 people on Zepbound had nausea, depending on the dose, against 8 in 100 on a placebo (dummy injection).1
- Pancreas and gallbladder. The label warns of pancreatitis (inflammation of the pancreas) and gallbladder problems, and links gallbladder events to weight loss.1
- Thyroid warning. Don’t use Zepbound with a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer), or with MEN 2 (multiple endocrine neoplasia type 2, an inherited condition that causes gland tumors).1
- Birth control pills. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.1
Read the full picture
Related questions
Sources
- Eli Lilly. Zepbound (tirzepatide) US prescribing information (sections 2.1, 2.2, 5.4, 6.1, Table 1), Medication Guide and Instructions for Use, revised 08/2026. US label. uspl.lilly.com
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038. PMID 35658024. doi.org · PubMed
- ClinicalTrials.gov. A study of tirzepatide in participants with obesity or overweight (SURMOUNT-1), NCT04184622: study arms and dosing. clinicaltrials.gov
- Eli Lilly. Zepbound coverage and savings, information for healthcare professionals: self-pay prices by dose and the 2.5 mg footnote. Maker’s page, checked Oct 19, 2026. zepbound.lilly.com
- Neighborhood Health Plan of Rhode Island. Weight Loss Management: Wegovy, Zepbound. Effective 01/2026, reviewed 08/2025 (Medicaid portion of Medicare plan). Plan policy. nhpri.org (PDF)
- Cigna National Formulary. Weight Loss: Zepbound Drug Quantity Management Policy, Per Days. Review date 10/30/2024, revised to 07/16/2025; see the 01/08/2025 revision. Plan policy. cigna.com (PDF)
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of Oct 1, 2026. fda.gov
- US Food and Drug Administration. Understanding unapproved use of approved drugs “off label”. Content current as of Feb 5, 2018. fda.gov
- MedlinePlus (US National Library of Medicine). Recognizing medical emergencies. Medical Encyclopedia, review date 1/8/2025. medlineplus.gov
Last checked Oct 19, 2026 · Next review due Apr 19, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Oct 19, 2026. The ‘What people report’ section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call 911. How we write